Tracking Prescription Volumes by Channel: 3QTD26: Y/Y TRx +1.5% (+0.8% Ex-Vax and Ex-GLP-1)

Research evidence excerpt

Tracking Prescription Volumes by Channel: 3QTD26: Y/Y TRx +1.5% (+0.8% Ex-Vax and Ex-GLP-1)

as only a single factor in making their investment decision.

For further information on the ways in which UBS Global Research manages conflicts and maintains independence of its research products, historical performance

information and certain additional disclosures concerning UBS Global Research recommendations, please visit https://www.ubs.com/disclosures.

UBS Global Research will initiate, update and cease coverage solely at the discretion of UBS Global Research Management, which will also have sole discretion on

the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information

in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those

assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different

results.

UBS Global Research may utilise artificial intelligence tools (“AI Tools”) in the preparation of this document. Notwithstanding any such use of AI Tools, this

document has undergone human review.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of

gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas

within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by UBS